Warning Letter — Fagron BV
The FDA issued a Warning Letter to Fagron BV on May 12, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
This action directly affects Fagron BV and may impact stakeholders involved in the pharmaceutical supply chain and compounding sectors that utilize their materials or services.
A Warning Letter from CDER signifies that the FDA has identified significant violations of regulatory requirements. This could lead to further enforcement actions, such as import alerts or the withholding of product approvals, if the identified deficiencies are not remediated to the agency's satisfaction. The source does not specify the exact nature of the violations, but typically these letters relate to CGMP or labeling non-compliance.
Quality and Regulatory teams should review documentation and facility standards against current pharmaceutical compliance requirements. Immediate internal audits of manufacturing or distribution processes may be appropriate to identify potential gaps in quality systems.
FDA Warning Letter issued to: Fagron BV. 05/12/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-bv-724551-05122026
Open in openFDA / FDA.gov